ENDV (Endonovo Therapeutics) Total Equity: $-27.82 Mil (As of Jun. 2025)


What is Endonovo Therapeutics Total Equity?

Endonovo Therapeutics ENDV Total Equity is $-27.82 Mil as of Jun. 2025. The stock has 3 warning signs investors should review.

Endonovo Therapeutics's total equity for the quarter that ended in Jun. 2025 was $-27.82 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Endonovo Therapeutics Total Equity Historical Data

* Premium members only.

The historical data trend for Endonovo Therapeutics's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Endonovo Therapeutics Total Equity Chart

Endonovo Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -14.37 -15.77 -32.18 -24.11 -26.80

Endonovo Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -25.48 -26.18 -26.80 -27.27 -27.82

Endonovo Therapeutics Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Endonovo Therapeutics's Total Equity for the fiscal year that ended in Dec. 2024 is calculated as

Total Equity=Total Assets(Q: Dec. 2024 )-Total Liabilities(Q: Dec. 2024 )
=0.018-26.822
=-26.80

Endonovo Therapeutics's Total Equity for the quarter that ended in Jun. 2025 is calculated as

Total Equity=Total Assets(Q: Jun. 2025 )-Total Liabilities(Q: Jun. 2025 )
=0.018-27.842
=-27.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $-27.82 Mil mean?
Endonovo Therapeutics (ENDV) has a Total Equity of $-27.82 Mil as of Jun. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Endonovo Therapeutics and its competitors.
Is Endonovo Therapeutics' Total Equity too high?
Endonovo Therapeutics' current Total Equity is $-27.82 Mil.
How does Endonovo Therapeutics' Total Equity compare to RGBP and IOBTQ?
Endonovo Therapeutics' Total Equity of $-27.82 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Endonovo Therapeutics and its competitors. Endonovo Therapeutics's current Total Equity is $-27.82 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Endonovo Therapeutics stock overvalued right now?
Endonovo Therapeutics (ENDV) has a current Total Equity of $-27.82 Mil. The current Total Equity is $-27.82 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Endonovo Therapeutics (ENDV), the current Total Equity is $-27.82 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Endonovo Therapeutics Business Description

Address 6320 Canoga Avenue, 15th Floor, Woodland Hills, CA, USA, 91367
Endonovo Therapeutics Inc develops, manufactures and distributes revolutionary medical devices that utilize Pulsed Electro Magnetic Field (PEMF) therapy that are focused on the rapid recovery of wounds and reduction of pain, edema and inflammation on and in the human body.